| __timestamp | Agios Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 1271353000 |
| Thursday, January 1, 2015 | 141827000 | 1620577000 |
| Friday, January 1, 2016 | 220163000 | 2052295000 |
| Sunday, January 1, 2017 | 292681000 | 2075142000 |
| Monday, January 1, 2018 | 341324000 | 2186100000 |
| Tuesday, January 1, 2019 | 410894000 | 3036600000 |
| Wednesday, January 1, 2020 | 367470000 | 2735000000 |
| Friday, January 1, 2021 | 256973000 | 2908100000 |
| Saturday, January 1, 2022 | 279910000 | 3592500000 |
| Sunday, January 1, 2023 | 288903000 | 4439000000 |
| Monday, January 1, 2024 | 301286000 | 5132000000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Regeneron consistently outspent Agios, with its R&D expenses peaking at approximately $4.4 billion in 2023, a staggering 340% increase from 2014. In contrast, Agios's R&D spending grew by about 188% over the same period, reaching nearly $289 million in 2023. This disparity highlights Regeneron's aggressive pursuit of new therapies, while Agios adopts a more measured approach. As the biotech landscape evolves, these strategic choices will shape their future innovations and market positions. Understanding these trends offers valuable insights into the companies' long-term visions and potential impacts on the healthcare industry.
Regeneron Pharmaceuticals, Inc. or argenx SE: Who Invests More in Innovation?
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Galapagos NV
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Comparing Innovation Spending: Ascendis Pharma A/S and Agios Pharmaceuticals, Inc.
Analyzing R&D Budgets: Grifols, S.A. vs Agios Pharmaceuticals, Inc.
Analyzing R&D Budgets: Corcept Therapeutics Incorporated vs Agios Pharmaceuticals, Inc.
Analyzing R&D Budgets: Viking Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: Agios Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.